Upcoming Login Downtime

We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.

For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Management Tracks

Ancestry’s Georgiadis joins Flagship as CEO-partner

Plus Melton rejoining Sanna at Vertex and updates from CARsgen, Third Harmonic and more

April 8, 2022 12:26 AM UTC

Margo Georgiadis became CEO-Partner at Flagship Pioneering, where she will be the CEO of a company in stealth mode and play a key role in the VC’s leverage AI and machine learning and preemptive health and medicine initiatives. Georgiadis was president and CEO at Ancestry.com until January 2021, and “endurance partner in residence” at General Catalyst. She was president, Americas at Google Inc., CEO at Mattel Inc., COO at Groupon Inc., and partner at McKinsey and Co. for 14 years.

Douglas Melton will join Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) full time as the company’s first distinguished Vertex fellow on May 2, according to an internal memo. In this role, he will lead a distinct research group within Vertex Cell and Genetic Therapies (VCGT) focused on fundamental human biology, and report to EVP, Chief of Cell and Genetic Therapies and VCGT Site Head Bastiano Sanna. A co-founder of Gilead Sciences Inc. (NASDAQ:GILD), Melton also founded Semma Therapeutics Inc., which Vertex acquired in 2019 for $950 million in cash. Sanna was CEO of Semma...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article